Dr. Clay Siegall is currently the CEO and founder of Seattle Genetics. The firm is a biotech firm that is based in Seattle and focuses on the development of targeted therapy drugs for diseases that have not experienced substantial mortality improvements for years.
Dr. Siegall attended the University of Maryland where he pursued a Bachelor of Science Degree in zoology. Siegall to further his education went to George Washington University where he was awarded a Ph.D. in Genetics.
Seattle Genetics like other Startups had humble beginnings and challenges. The company was founded by Dr. Siegall in 1998, and today it has grown to be one of the top companies in the targeted therapy industry. Under Siegall leadership, the company has been able to achieve a lot and among its achievements include the development of the first FDA- approved antibody drug conjugate. In addition, the company has developed a robust pipeline of more than twenty drugs and has strategically partnered with leading drug manufacturing companies such as Bayer, Genentech, and Pfizer among others.
Seattle Genetics boasts of being one of the leading firms in cancer research. Dr. Siegall has big dreams for the company and is working towards expanding the company with the development of new drugs and increasing the number of potential indications in the existing drug portfolio.
Dr. Clay Siegall aims at revolutionizing the cancer treatment method through the introduction of tolerable and effective targeted therapies drugs as opposed to the old existing methods such as chemotherapies.
Dr. Siegall Started Seattle genetics due to his interests in medicine, the power of technology and wanted to save lives. Siegall became specifically interested in studying cancer while studying zoology and the University of Maryland and more so when a relative of his got cancer. The treatment methods to Siegall appeared to be brutal, and his relative almost lost life not because of cancer but because of Chemotherapy.
There are a number of ways through which the company makes money the first one being through the selling of the firms proprietary drugs. The company also earns revenue from production partnerships, technology licensing and processes that the firm has developed. According to Siegall, the company became profitable almost a decade after launching the IPO. It was not all rosy for the Journey to growing Seattle Genetics to where it is today, and there was a time the operating capital was getting depleted and the business almost collapsed but through sheer hard work Siegall was able to turn things around. The company attributes its successes to the sales and marketing team and the fact that it manufactures unique products.